Ethics Violations of PharmaCARE
When viewing the behavior of PharmaCARE in marketing and selling its drug AD23, there are a number of ethical issues that the company is brazenly violating. The first and most brazen violation of marketing ethics was creating a subsidiary (CompCARE) to do the marketing for AD23 in order to circumvent the regulation of the FDA. This is a clear violation of the ethical need to comply with government regulation, which businesses are expected to do. By creating CompCARE and shuffling off the product to them, creating a hasty renovation and shifting of resources, the goal was to prevent the FDA from being able ...
